Teclistamab-cqyv (Tecvayli) led to clinically meaningful responses in patients with heavily pretreated multiple myeloma who ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 best debt-free stocks to invest in right now. The company ...

A high-stakes legal fight between Regeneron and Amgen over the blockbuster eye drug Eylea is putting the U.S. patent system ...

Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks. Find out why REGN ...

AbbVie has placed a high price on that potential, coughing up $700 million for a phase 1 candidate and offering up to $1.225 ...

During a live event, Hans Lee, MD, and participants shared their perspectives on current and upcoming treatment approaches in ...

During a live event, Alfred L. Garfall, MD, discussed talquetamab dosing strategies and efficacy after dose reduction in ...

Multiple myeloma is a rare blood cancer of the plasma cells in bone marrow -- the soft, spongy interior of bone where all blood cells are produced. Plasma cells are a type of white blood cell that ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the most undervalued large cap stocks to buy according to analysts. On ...

New criteria make high-risk smoldering multiple myeloma treatable, opening door to future 'chronic' disease status ...

Accelerated approval was based on results from the Phase I/II LINKER-MM1 trial, which showed a 70% objective response rate in ...

The Food and Drug Administration (FDA) has granted accelerated approval to Lynozyfic™ (linvoseltamab-gcpt) for the treatment of adult patients with ...